In early 2026, a growing body of research began to highlight an unexpected intersection between prenatal screening and oncology: the detection of maternal cancers through cell-free DNA (cfDNA) screening tests originally designed to assess fetal chromosomal abnormalities. These non-invasive prenatal tests (NIPT), which analyze fragments of DNA circulating in a pregnant person’s bloodstream, have long been celebrated for their ability to screen for conditions like trisomy 21, 18, and 13 with high accuracy. Still, as their use expanded globally, clinicians started observing cases where abnormal cfDNA results did not reflect fetal pathology but instead signaled undiagnosed malignancies in the pregnant individual.
This phenomenon, while still relatively rare, has prompted renewed discussion about the dual utility of cfDNA screening—not only as a tool for fetal assessment but also as a potential window into maternal health. Experts emphasize that when cfDNA screening yields unexpected or inconclusive results, particularly involving multiple chromosomal anomalies or patterns inconsistent with fetal genotypes, it may warrant further oncological investigation. The implications are significant: early detection of cancer during pregnancy can dramatically improve prognosis, yet diagnosing malignancy in this context remains complex due to physiological changes that mimic or obscure tumor markers.
Recognizing the require for clearer clinical guidance, major medical societies have begun to reevaluate protocols surrounding cfDNA screening. In late 2025, the International Society for Prenatal Diagnosis (ISPD) issued updated recommendations advising obstetricians to consider maternal malignancy as a possible explanation for atypical cfDNA findings, especially when fetal ultrasound shows no abnormalities. Similarly, the American College of Obstetricians and Gynecologists (ACOG) reinforced in its 2026 practice bulletin that abnormal results should prompt genetic counseling and, when indicated, maternal diagnostic workup—including imaging and tissue biopsy—rather than assuming fetal pathology.
These developments reflect a broader shift in how prenatal screening is understood: not merely as a fetal-focused tool, but as a moment of systemic health assessment during a period when many individuals engage deeply with the healthcare system. For oncologists, the possibility of identifying cancers earlier—sometimes before symptoms arise—represents a promising, albeit still emerging, avenue for intervention. For expectant parents, it introduces new layers of complexity in interpreting screening results, underscoring the importance of clear communication and multidisciplinary care.
How Cell-Free DNA Screening Works and What It Can Reveal
Cell-free DNA screening relies on the presence of small DNA fragments in the bloodstream, a natural byproduct of cellular turnover. During pregnancy, this pool includes DNA from both the pregnant individual and the placenta, which closely mirrors the fetal genome. By sequencing these fragments and analyzing their chromosomal representation, laboratories can estimate the likelihood of certain fetal aneuploidies. The test is typically performed from the 10th week of gestation onward and requires only a maternal blood draw.
Under normal circumstances, the chromosomal profile of cfDNA aligns with the expected fetal and maternal contributions. However, when a malignancy is present in the pregnant person, tumor-derived DNA can enter the bloodstream and alter this balance. Because cancer cells often exhibit chromosomal instability—gaining or losing large segments of DNA—their contribution to the cfDNA pool may manifest as widespread, seemingly random chromosomal abnormalities that do not conform to patterns seen in fetal conditions.
In such cases, the sequencing data may reveal gains or losses across multiple chromosomes simultaneously, a pattern that is highly unusual in fetal aneuploidies but characteristic of certain cancers, including lymphoma, colorectal carcinoma, and breast cancer. Laboratories that perform cfDNA screening have begun to flag these atypical results, though interpretations vary. Some report them as “inconclusive” or “failed,” while others provide detailed chromosomal maps that suggest a non-fetal origin.
The challenge lies in distinguishing between true fetal abnormalities, maternal constitutional variants (such as balanced translocations), and malignancy-related changes. This requires expertise in both prenatal genetics and oncogenomics—a combination still rare in clinical practice. Many atypical findings may go under-investigated unless clinicians are specifically alerted to the possibility of maternal cancer.
Clinical Recognition and Evolving Guidelines
The first well-documented cases of maternal cancer detection via cfDNA screening emerged in the early 2020s, primarily in research settings. A 2022 study published in JAMA Oncology described several instances where abnormal NIPT results led to the diagnosis of maternal lymphomas and solid tumors, often at early stages. Since then, case reports have accumulated, prompting professional organizations to formalize awareness.
In its 2025 update, the ISPD explicitly stated that “persistent, unexplained cfDNA anomalies involving multiple chromosomes, particularly when fetal anatomy is normal, should raise suspicion for maternal malignancy and prompt appropriate evaluation.” The society emphasized that genetic counselors play a key role in interpreting these results and guiding patients toward next steps, which may include referral to maternal-fetal medicine specialists or oncologists.
ACOG’s 2026 guidance echoes this caution, advising that “any cfDNA result suggestive of a chromosomal abnormality should be followed by diagnostic confirmation—such as amniocentesis or chorionic villus sampling—if fetal involvement is suspected. If fetal testing is normal or inconclusive, maternal evaluation should be considered, especially in the presence of clinical symptoms or persistent abnormal screening results.”
These recommendations mark a shift from viewing cfDNA screening as exclusively fetal-focused to recognizing its potential role in maternal health surveillance. However, experts caution that the test is not designed or validated as a cancer screening tool. Its sensitivity and specificity for malignancy remain undefined, and false positives or negatives could occur. CfDNA should not replace established cancer screening methods, such as mammography or colonoscopy, but rather serve as a possible indicator prompting further assessment when results are anomalous.
Who Is Affected and What the Data Suggest
Maternal cancer during pregnancy is uncommon but not rare. Estimates suggest that approximately 1 in 1,000 pregnancies is associated with a malignancy diagnosis, with breast cancer, cervical cancer, lymphoma, and melanoma being among the most frequently reported types. The average age of affected individuals tends to be slightly higher than the general pregnant population, reflecting broader trends in delayed childbearing and age-related cancer risk.
While no large-scale studies have yet quantified how often cfDNA screening detects maternal cancer, indirect evidence suggests the yield is low but meaningful when it occurs. A 2023 retrospective analysis of over 100,000 NIPT results from a major U.S. Laboratory found that fewer than 0.1% showed patterns strongly suggestive of maternal malignancy. However, in those cases, follow-up confirmed cancer in a significant proportion—highlighting the test’s potential as a triage tool in select scenarios.
cfDNA screening is most commonly offered in high-resource settings and may not be accessible globally. In regions where prenatal screening is limited or where oncological follow-up is constrained, the potential benefits of incidental cancer detection may not be fully realized. Equity in access to both prenatal care and cancer diagnostics remains a critical consideration as this field evolves.
What Happens Next: Follow-Up and Care Pathways
When an atypical cfDNA result raises concern for maternal malignancy, the next steps typically involve a combination of imaging, laboratory tests, and, if necessary, tissue sampling. Ultrasound and magnetic resonance imaging (MRI)—considered safe during pregnancy when clinically indicated—can help identify tumors, particularly in accessible organs like the breast, liver, or lymph nodes. Blood tests such as complete blood count, lactate dehydrogenase (LDH), and cancer-associated markers (e.g., CA-125, CEA) may provide supportive evidence, though none are definitive on their own.
If imaging reveals a suspicious lesion, a biopsy may be performed to obtain a histopathological diagnosis. Core needle biopsy is generally preferred over surgical excision when feasible, and many procedures can be conducted safely during pregnancy with appropriate precautions. Multidisciplinary tumor boards, involving obstetricians, oncologists, radiologists, and pathologists, are often convened to weigh treatment options that balance maternal health with fetal safety.
Treatment decisions depend on the cancer type, stage, gestational age, and individual preferences. Some therapies, including certain chemotherapy regimens, can be administered during pregnancy—particularly after the first trimester—with minimal risk to the fetus. Radiation therapy is generally avoided due to potential fetal harm, though shielding techniques may allow limited use in specific cases. Surgery is often considered when anatomically feasible and timed to minimize uterine stress.
Throughout this process, clear communication is essential. Patients may experience anxiety not only about their own health but also about potential impacts on the pregnancy. Genetic counselors and maternal-fetal medicine specialists play a vital role in explaining cfDNA limitations, interpreting results, and supporting informed decision-making.
Ongoing Research and Future Directions
Researchers are actively exploring ways to refine cfDNA analysis to better distinguish between fetal and maternal sources of chromosomal abnormalities. Advances in methylation profiling, fragment size analysis, and haplotype-based sequencing are improving the ability to trace DNA fragments to their tissue of origin. These techniques could one day allow laboratories to report not just chromosomal counts but also the likely cellular source—whether placental, fetal, or maternal—thereby increasing the specificity of cfDNA screening for maternal conditions.
Some investigational approaches aim to detect cancer-specific mutations or epigenetic signatures in cfDNA, moving beyond chromosomal instability toward molecular markers associated with known malignancies. While such applications remain experimental, they represent a promising frontier in liquid biopsy technology—one that could eventually integrate prenatal screening with broader early cancer detection efforts.
Clinical trials are underway to evaluate the performance of enhanced cfDNA assays in pregnant populations, with endpoints including cancer detection rates, false positive rates, and impact on maternal outcomes. Results from these studies, expected in the coming years, will help determine whether cfDNA screening can be reliably adapted for dual-purpose use or whether separate maternal-focused assays are needed.
Key Considerations for Expectant Parents and Healthcare Providers
For individuals undergoing cfDNA screening, it is helpful to understand that an abnormal result does not automatically mean there is a problem with the fetus—or with the pregnant person. Instead, it signals a need for further evaluation to clarify the source of the anomaly. Asking questions about what the result means, what follow-up tests are recommended, and how long the process may take can reduce uncertainty and support informed choices.
Healthcare providers are encouraged to stay informed about the evolving understanding of cfDNA limitations and possibilities. When results are atypical, initiating a conversation about potential maternal causes—without causing alarm—can open the door to timely evaluation. Institutions may benefit from developing clear pathways for managing unexpected cfDNA findings, including access to genetic counseling, maternal-fetal medicine, and oncology services.
As with any screening test, cfDNA offers probabilities, not certainties. Its value lies not in definitive diagnosis but in risk stratification—identifying those who may benefit from closer look. In the context of maternal health, this role is still being defined, but early signals suggest it could become a meaningful component of comprehensive prenatal care.
At present, there is no universal recommendation to pursue oncological evaluation solely based on cfDNA results. Instead, the approach remains cautious and individualized, guided by clinical judgment, patient history, and the specific characteristics of the test outcome. The next major checkpoint in this evolving landscape is the anticipated release of updated consensus guidelines from the International Society of Prenatal Medicine (ISPM), expected in late 2026, which will likely address the integration of maternal health considerations into prenatal screening frameworks.
If you have undergone cfDNA screening and received an unexpected result, or if you are a clinician navigating these complex scenarios, sharing your experience can help others better understand the realities of modern prenatal testing. Consider joining the conversation by commenting below or sharing this article with colleagues and networks interested in the intersection of reproductive health and oncology.